Journal of Neuro-Oncology

, Volume 82, Issue 1, pp 91–93

A lipoxygenase inhibitor in breast cancer brain metastases

Authors

    • Foundation for Collaborative Medicine and Research
Clinical–Patient Studies

DOI: 10.1007/s11060-006-9248-4

Cite this article as:
Flavin, D.F. J Neurooncol (2007) 82: 91. doi:10.1007/s11060-006-9248-4

Abstract

The complication of multiple brain metastases in breast cancer patients is a life threatening condition with limited success following standard therapies. The arachidonate lipoxygenase pathway appears to play a role in brain tumor growth as well as inhibition of apoptosis in in-vitro studies. The down regulation of these arachidonate lipoxygenase growth stimulating products therefore appeared to be a worthwile consideration for testing in brain metastases not responding to standard therapy. Boswellia serrata, a lipoxygenase inhibitor was applied for this inhibition. Multiple brain metastases were successfully reversed using this method in a breast cancer patient who had not shown improvement after standard therapy. The results suggest a potential new area of therapy for breast cancer patients with brain metastases that may be useful as an adjuvant to our standard therapy.

Keywords

CancerLipoxygenaseBoswellia serrata Oxidoreductase inhibitor LOX inhibitors Lipoxygenase inhibitor Brain CancerBreast CancerMetastasesBreast Cancer RemissionArachidonate: Oxygen oxidoreductase Herceptin

Copyright information

© Springer Science+Business Media, Inc. 2006